Protara Therapeutics Investor Relations Material
Latest events
Status Update
Protara Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Protara Therapeutics Inc
Access all reports
Protara Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing transformative therapies for cancer and rare diseases. Their lead program, TARA-002, is an investigational cell therapy aimed at treating lymphatic malformations, based on the broad immunopotentiator OK-432. Additionally, Protara is developing intravenous choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure-associated liver disease. The company is headquartered in NYC, and its shares are listed on the Nasdaq.
Key slides for Protara Therapeutics Inc
43rd Annual J.P. Morgan Healthcare Conference 2025
Protara Therapeutics Inc
43rd Annual J.P. Morgan Healthcare Conference 2025
Protara Therapeutics Inc
Latest articles
)
Eli Lilly: The Pharma Giant Behind Mounjaro and Zepbound
Eli Lilly's journey from insulin pioneer to global pharma giant, leading innovation in diabetes, obesity, and the future of metabolic health.
30 Jun 2025
)
500 Years of Craft, One Family Legacy: Beretta Holding's Global Expansion
How Beretta Holding managed to transform from a 16th-century gun barrel producer into a global industrial group while preserving 500 years of legacy.
27 Jun 2025
)
Shuntaro Furukawa: The Sixth President of Nintendo
Shuntaro Furukawa, Nintendo's sixth president, went from a childhood fan to leading the company through global expansion and the launch of Switch 2.
23 Jun 2025
Ticker symbol
TARA
Country
🇺🇸 United States